This article is more than 5 years old. Information may no longer be current.
Intraocular anti-VEGF benefits patients with macular edema secondary to CRVO
Click Here to Manage Email Alerts
Patients with macular edema secondary to central retinal vein occlusion experienced improved visual acuity and significantly reduced macular edema after intraocular injections of bevacizumab every 6 weeks for 12 months, a study found.
The 12-month prospective analysis was composed of a 6-month randomized sham injection-controlled, double-masked clinical trial and a 6-month open-label extension.
Sixty patients with macular edema secondary to CRVO were split into two groups of 30 patients. The control group received sham injections every 6 weeks for 6 months before receiving intraocular injections of Avastin (bevacizumab, Genentech) every 6 weeks for the final 6 months. The other group received intraocular injections of bevacizumab every 6 weeks for the entire 12 months.
At the conclusion of the study, 18 patients (60%) in the bevacizumab-only group gained 15 letters or more, while 10 patients (33.3%) in the control group gained 15 letters or more (P < .05). Best corrected visual acuity improved by 16 letters in the bevacizumab-only group compared with 4.6 letters in the control group (P < .05).
The study authors subsequently performed an unplanned retrospective analysis and found that patients who were older than 70 years experienced significantly worse outcomes when intraocular bevacizumab treatment was delayed. These patients in the control group lost 1.4 letters, while patients younger than 70 years in the bevacizumab-only group gained 20.1 letters (P < .003).
Click Here to Manage Email Alerts